Pharmaceutical

MDbio Start Clinical Trials for Pharmaceutical-Grade Products That Target Sleeplessness, Anxiety and Pain; Expected Retail From 2023

Los Angeles, CA, July 14, 2022 (GLOBE NEWSWIRE) -- MDbio are a leading plant-based, wellness solution who provide safe, pharmaceutical-grade...

New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration

In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two...

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets

Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...

Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies

Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...

Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...

Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis

 Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...

error: Content is protected !!